Bruce C Tiu

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.

N. LeBoeuf, M. Asgari, V. Naranbhai, 2022, JAMA dermatology.

A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment

J. Connors, E. Brea, Bruce C Tiu, 2021, Postgraduate medicine.

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

J. Naidoo, K. Reynolds, M. Sise, 2022, Journal for ImmunoTherapy of Cancer.

Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study.

Aditya M. Sharma, S. Goldhaber, G. Piazza, 2023, Thrombosis research.

Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study

Aditya M. Sharma, S. Goldhaber, G. Piazza, 2023, Thrombosis Research.

On Defining Global Catastrophic Biological Risks

Megan J. Palmer, D. Relman, Bruce C Tiu, 2017, Health security.

Pre-Existing Autoimmune Disease and Mortality in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy.

K. Reynolds, S. Kwatra, Y. Semenov, 2022, Journal of the National Cancer Institute.

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study

D. Leaf, K. Reynolds, M. Sise, 2023, The oncologist.